Impact of compound mutations I1171N + F1174I and I1171N + L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights

Dual‐Inhibition of Human N ‐Myristoyltransferase Subtypes Halts Common Cold Pathogenesis: Atomistic Perspectives from the Case of IMP‐1088**

(2021) Clement Agoni et al.   CHEMISTRY & BIODIVERSITY

Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor

(2020) Justin A. Caravella et al.   JOURNAL OF MEDICINAL CHEMISTRY

Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives

(2020) Elliasu Y. Salifu et al.   COMPUTATIONAL BIOLOGY AND CHEMISTRY

In silico screening of hundred phytocompounds of ten medicinal plants as potential inhibitors of nucleocapsid phosphoprotein of COVID-19: an approach to prevent virus assembly

(2020) Rajan Rolta et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

(2019) Koutaroh Okada et al.   EBioMedicine

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

(2019) Ibiayi Dagogo-Jack et al.   CLINICAL CANCER RESEARCH

Halting ionic shuttle to disrupt the synthetic machinery—Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis

(2019) Elliasu Y. Salifu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer

(2019) Emma Pailler et al.   CLINICAL CANCER RESEARCH

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

(2019) Gonzalo Recondo et al.   CLINICAL CANCER RESEARCH

Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors

(2018) Mi Ran Yun et al.   CANCER RESEARCH

Allosteric inhibition abrogates dysregulated LFA-1 activation: Structural insight into mechanisms of diminished immunologic disease

(2018) Maryam Abdullahi et al.   COMPUTATIONAL BIOLOGY AND CHEMISTRY

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

(2018) Satoshi Yoda et al.   Cancer Discovery

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces

(2018) Hao Huang   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

(2018) Benjamin J Solomon et al.   LANCET ONCOLOGY

Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation

(2017) Jikui Guan et al.   Cancers

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib

(2016) Shiro Fujita et al.   Journal of Thoracic Oncology

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

(2015) Helen Y. Zou et al.   CANCER CELL

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

(2015) Gorjan Hrustanovic et al.   NATURE MEDICINE

Residue interaction network analysis of Dronpa and a DNA clamp

(2014) Guang Hu et al.   JOURNAL OF THEORETICAL BIOLOGY

Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald

(2013) Romelia Salomon-Ferrer et al.   Journal of Chemical Theory and Computation

ALKin Lung Cancer: Past, Present, and Future

(2013) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells

(2012) T. Yamada et al.   CLINICAL CANCER RESEARCH

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Exploring the Molecular Mechanism of Cross-Resistance to HIV-1 Integrase Strand Transfer Inhibitors by Molecular Dynamics Simulation and Residue Interaction Network Analysis

(2012) Weiwei Xue et al.   Journal of Chemical Information and Modeling

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Protein stability, flexibility and function

(2010) Kaare Teilum et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS